Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, Rump LC, Persu A, Basile J, Bloch MJ, Daemen J, Lobo MD, Mahfoud F, Schmieder R, Sharp ASP, Weber MA, Sapoval M, Fong P, Pathak A, Lantelme P, Hsi D, Bangalore S, Witkowski A, Weil J, Kably B, Barman NC, Reeve-Stoffer H, Coleman L, Mcclure CK, Kirtane AJ (2021)
Publication Type: Journal article
Publication year: 2021
Book Volume: 397
Pages Range: 2476-2486
Journal Issue: 10293
DOI: 10.1016/S0140-6736(21)00788-1
Background Endovascular renal denervation reduces blood pressure in patients with mild-to-moderate hypertension, but its efficacy in patients with true resistant hypertension has not been shown. We aimed to assess the efficacy and safety of endovascular ultrasound renal denervation in patients with hypertension resistant to three or more antihypertensive medications.
APA:
Azizi, M., Sanghvi, K., Saxena, M., Gosse, P., Reilly, J.P., Levy, T.,... Kirtane, A.J. (2021). Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. The Lancet, 397(10293), 2476-2486. https://doi.org/10.1016/S0140-6736(21)00788-1
MLA:
Azizi, Michel, et al. "Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial." The Lancet 397.10293 (2021): 2476-2486.
BibTeX: Download